文献速递炎症性肠病

基于NUDT15基因分型的剂量优化策略减少克罗恩病硫嘌呤治疗相关白细胞减少:随机临床试验

Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2021-09-25

在中国克罗恩病患者中,基于NUDT15 C415T基因分型的剂量优化策略(CC型标准剂量、CT型50%剂量、TT型换药)相比对照组降低了硫嘌呤诱导的白细胞减少发生率(23.7% vs 32.4%,P=0.049),且不显著影响疗效。CT亚组中干预组白细胞减少发生率显著低于对照组(31.3% vs 65.1%)。

要点

  • NUDT15 C415T基因分型指导的剂量优化可降低中国克罗恩病患者硫嘌呤相关白细胞减少风险。
  • CT基因型患者接受50%标准剂量可显著减少白细胞减少,TT型建议换用替代药物。
  • 该策略在降低白细胞减少的同时未显著影响维持无激素缓解的疗效。

核心结论

  • 在中国克罗恩病患者中,基于NUDT15 C415T的剂量优化减少了硫嘌呤诱导的白细胞减少率,且对疗效无显著影响。
  • 对杂合子(CT)使用50%剂量、对纯合子(TT)使用替代药物是可行的策略。

研究设计与样本

  • 随机临床试验,纳入中国两家医院有硫嘌呤适应症的克罗恩病患者。
  • 干预组按NUDT15 C415T基因型给药:CC型标准剂量,CT型50%标准剂量,TT型替代药物;对照组为标准剂量。
  • 主要终点为硫嘌呤诱导的白细胞减少(<3.5 × 10^9/L);次要终点为其他不良事件发生率和第36周维持无激素缓解的疗效。
  • 干预组n=52,对照组n=66。

主要发现

  • 干预组白细胞减少发生率低于对照组(23.7% vs 32.4%,P=0.049,RR=0.73,95% CI 0.53-1.00)。
  • CT亚组中干预组(n=10)白细胞减少发生率显著低于对照组(n=28)(31.3% vs 65.1%,RR=0.48,95% CI 0.28-0.84)。
  • 随访期间两组其他不良事件及治疗疗效无显著差异。

关键数值与推荐

  • 主要终点白细胞减少定义为<3.5 × 10^9/L。
  • CT基因型接受50%标准剂量,TT基因型接受替代药物。
  • CT亚组干预组白细胞减少发生率31.3%(n=10),对照组65.1%(n=28),RR=0.48,95% CI 0.28-0.84。

临床怎么用

  • 对中国克罗恩病患者启动硫嘌呤治疗前可行NUDT15 C415T基因分型。
  • CT基因型患者可考虑将硫嘌呤剂量减至标准剂量的50%。
  • TT基因型患者建议换用替代药物而非硫嘌呤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Thiopurine S-methyltransferase (TPTM) is a well known biomarker for thiopurine-induced leucopenia, which has limited value in Asia. Instead, NUDT15 C415T is a promising predictor in Asia. AIMS: To explore whether an optimised strategy based on NUDT15 C415T genotypes affects thiopurine-induced leucopenia, as well as efficacy in Chinese patients with Crohn's disease. METHODS: Patients with Crohn's disease and indications for thiopurines were included from two hospitals in China. They were randomly assigned to either the intervention or the control group. In the intervention group, those with genotype CC received a standard dose (control group), those with CT genotype received 50% of the standard dose, those with TT genotype received alternative drugs. The primary endpoint was thiopurine-induced leucopenia (<3.5 × 109 /L). Secondary outcomes were the incidence of other adverse events and the efficacy for maintaining steroid-free remission at week 36. RESULTS: The rate of thiopurine-induced leucopenia was lower in the intervention group (n = 52) than in the control group (n = 66) (23.7% vs 32.4%, P = 0.049, RR = 0.73, 95% CI 0.53-1.00). In CT subgroup, the incidence of leucopenia in the intervention group (n = 10) was significantly lower than in the control group (n = 28) (31.3% vs 65.1%, RR = 0.48, 95% CI 0.28-0.84). Neither other adverse events nor treatment efficacy was significantly different between the two groups during follow-up. CONCLUSIONS: Among Chinese patients with Crohn's disease, dose optimisation by NUDT15 C415T reduced the rate of thiopurine-induced leucopenia, without significant influence on efficacy. Using 50% dose reduction for heterozygotes, and alternative drugs for homozygotes, are practicable strategies. Clinical trial number: NCT02929706.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chao K, Huang Y, Zhu X, et al. Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease. Aliment Pharmacol Ther. 2021. PMID: 34563096. doi:10.1111/apt.16600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。